Endocan is a key player in cardiovascular disease: A review

• Príomhchruthaitheoirí: Amina M. Alieva (Údar), Elena V. Reznik (Údar), Irina E. Baykova (Údar), Natalia V. Teplova (Údar), Liudmila M. Makeeva (Údar), Kira V. Voronkova (Údar), Nyurzhanna Kh. Khadzhieva (Údar), Anna V. Modestova (Údar), Gaiane G. Totolyan (Údar), Ramiz K. Valiev (Údar), Alexander M. Li (Údar), Irina A. Kotikova (Údar), Igor G. Nikitin (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: ZAO "Consilium Medicum", 2023-05-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

In recent years, the attention of scientists has been actively focused on studying the role of endocan as a biological marker of endothelial dysfunction in cardiovascular diseases. Until recent years, endocan has been studied in acute kidney injury, chronic kidney disease, and renal replacement ther...